sympathetic system sympathomimetic agents

28
SYMPATHETIC SYSTEM Sympathomimetic Agents

Upload: wilmet

Post on 07-Jan-2016

39 views

Category:

Documents


0 download

DESCRIPTION

SYMPATHETIC SYSTEM Sympathomimetic Agents. SYMPATHETIC SYSTEM Mostly activated during stressful situations Actions can be identified by reactions during “fright, fight, flight” Neurotransmitter at most post-ganglionic terminals is Noradrenaline Others: Adrenaline ( Brain, adrenal) - PowerPoint PPT Presentation

TRANSCRIPT

Page 1: SYMPATHETIC SYSTEM Sympathomimetic Agents

SYMPATHETIC SYSTEM

Sympathomimetic Agents

Page 2: SYMPATHETIC SYSTEM Sympathomimetic Agents

SYMPATHETIC SYSTEM

Mostly activated during stressful situations

Actions can be identified by reactions during “fright, fight, flight”

Neurotransmitter at most post-ganglionic terminals is NoradrenalineOthers: Adrenaline (Brain, adrenal) Adrenaline from adrenal medulla augments function during sympathetic activation

Dopamine : Basal ganglia, other parts of brain, ? Periphery

Page 3: SYMPATHETIC SYSTEM Sympathomimetic Agents

Synthesis Storage and Release and degradation of NA, DA, Adr

Page 4: SYMPATHETIC SYSTEM Sympathomimetic Agents

Storage and release of Catecholamines

• Storage in vesicles along with ATP and other substances

• Released by exocytosis

• Release is modified by presynaptic autoreceptors & heteroreceptorsα2 ↓β2 ↑

Page 5: SYMPATHETIC SYSTEM Sympathomimetic Agents

Termination of action of Catecholamines

1. Re-Uptake

2. Enzymatic degradation

3. Diffusion

4. Extra synaptic uptake

Page 6: SYMPATHETIC SYSTEM Sympathomimetic Agents
Page 7: SYMPATHETIC SYSTEM Sympathomimetic Agents

SUBTYPES OF ADRENERGIC RECEPTORS

ΑLPHA BETA

α1 α2 β1 β2 β3

1A

1B

1C

1D

2A

2B

2C

2D

Receptors are located PRE and POST-synapticallyPre-synaptic receptors modify release from the terminal

Page 8: SYMPATHETIC SYSTEM Sympathomimetic Agents

Receptor Transduction Agonist

Alpha 1

1A

1B

1C

1D

Alpha 2

2A

2B

2C

2D

Beta1

2

3

DA ( 1,2,4,5)

IP3 ; DAG (common)

+ Ca influx

? Ca influx

cAMP (common)+ K , Ca channels Ca channels

cAMP (common)

(D1,5), cAMP (D2,3,4)

Epi > NE >> Iso( Phenylephrine, Methoxamine)

Epi > NE >> Iso( Clonidine )

Iso > Epi > NE Dobutamine TerbutalineIso = NE > Epi

DA,

Transduction mechanisms and actions of adrenergic receptor subtypes

Page 9: SYMPATHETIC SYSTEM Sympathomimetic Agents

Organ system effects of sympathetic activation

EYE

Radial muscle

Ciliary muscle

I.O. Pressure

Lacrymal glands

CVS

HEART

SA node; Atria

AV node

Purkinje Ventricles

Blood Vessels

1

2

1; 2

(& 1)

(1 & 2)

2

D1

Mydriasis

Relaxation & accomodation

Aquous outflow

Increase aquous formation

Secretion +

HR; contractility & CV

automaticity,

idioventricular pacemakers +++

constriction (Skin, spalnchnic )

relaxation (Skeletal muscle)

relaxation (Renal, coronary, cerebral)

Page 10: SYMPATHETIC SYSTEM Sympathomimetic Agents

Organ system effects of sympathetic activation

BRONCHI (SmM)

GIT

GENITOURINARY

Uterus

Bladder

trigone, sphincter

detrussor

Male sexual organs

2

1

1

2

1

2

relaxation

relaxation ( ACh release)

relaxation (direct - smooth muscle)

contraction of sphincters

contraction (pregnant)

relaxation (Preg. & Non-preg)

contraction

relaxation

ejaculation

Page 11: SYMPATHETIC SYSTEM Sympathomimetic Agents

Organ system effects of sympathetic activation

METABOLIC

Fat cells

Liver

Pancreas

J-G cells

2

(& )

2

1

2

Lipolysis; Inhibit lipolysis

Glycogenolysis

Insulin secretion

Insulin secretion

Renin rsecretion Renin secretion

Page 12: SYMPATHETIC SYSTEM Sympathomimetic Agents
Page 13: SYMPATHETIC SYSTEM Sympathomimetic Agents

Targets for Pharmacological Interference Tyrosine hyhroxylase MPT NA

DOPA decarboxylase Methyldopa Pseudotransmitter*

Dopamine hydroxylase Disulfiram

Release of NA Tyramine Sympathomimetic

Amphetamine

Release of NA Guanethidine SympatholyticBretylium

Reuptake Cocaine, effect of NTImipramine indirect

mimetics

Reuptake into granules Reserpine Release Depletion

Page 14: SYMPATHETIC SYSTEM Sympathomimetic Agents

Targets for Pharmacological Interference

Presynaptic 2 Catecholamines release

Presynaptic 2 Catecholamines release

Presynaptic M ACh release

MAO Several metabolism

Extrasynaptic uptake PBZ, Steroids Effect

COMT Pyrogallol ---TalcaponeEntacapone

Page 15: SYMPATHETIC SYSTEM Sympathomimetic Agents

MethoxaminePhenylephrine

ClonidineMethyldopa*

ApraclonidineGuanfacineGuanabenz

TerbutalineAlbuterolFenoterolPirbuterol

Long ActingProcaterolSalmeterol

Isoprenaline (β1 & β2)Dobutamine (β1)IsoetharinePrenalterol

DA, NA, Adr

OxymetazolineXylometazolineNaphazoline

Sympathomimetic drugs

Indirectly actingDirectly acting

Catecholamines Non-Catecholamines

α1 agonists α2 agonists β2 agonists

Endogenous

Synthetic

TyramineAmphetamine

MixedEphedrine

Page 16: SYMPATHETIC SYSTEM Sympathomimetic Agents

ENDOGENOUS CATECHOLAMINES

Adrenaline Noradrenaline Dopamine

Page 17: SYMPATHETIC SYSTEM Sympathomimetic Agents

ENDOGENOUS CATECHOLAMINES

1. ADRENALINE (Epinephrine): Mainly from adrenal medulla (Also some neurons in brain)

Receptor actions : Both and ; Potency for >

All effects of stimulation of and receptors; but some are more evident.

Heart: rate, force, arrhythmias (high dose, rapid administration)

Page 18: SYMPATHETIC SYSTEM Sympathomimetic Agents

Blood Pressure: Adrenaline is one of the most potent vasoconstrictors

Pharmacological dose: ↑Force and rate of ventricular contraction (β1)

+ ↑Vascular resistance (skin, mucosa, kidney) (α)

+ ↑Marked venoconstriction

Lower dose: B.P. ( 2 more sensitive)

Cutaneous blood flow ; Skeletal muscle blood flow

Nett effect: C.O. & B.P. (systolic ; diastolic ±)

Page 19: SYMPATHETIC SYSTEM Sympathomimetic Agents

Dale’s Reversal Phenomenon

AdrPBZ

Mea

n a

rter

ial

blo

od

pre

ssu

re

Page 20: SYMPATHETIC SYSTEM Sympathomimetic Agents

Respiratory system: Bronchodilatation ( specially when constriction +nt)

CNS: Not marked ( poor BBB penetration)Large doses: Restlessness, apprehension, headache, tremor

Metabolic: Blood glucose ( insulin (2); glucose

uptake; glycogenolysis)(glucagon secretion - )

Mast cells : Stabilized

Page 21: SYMPATHETIC SYSTEM Sympathomimetic Agents

Absorption fate and excretion Orally ineffective (hydrolyzed by liver and gut) Absorption I.M > S.C. ; Given I.V. in emergencies ; Inhalation (nebulized)

Toxicity : due to and stimulation Mainly CVS: BP, vasoconstriction, tachycardia, arrhythmiaTherapeutic uses: Anaphylaxis ( I.M / I.V.) ( 0.3 – 0.5 ml of 1:1000) Cardiac arrest (May have to be given intra-cardiac )With local anaesthetics ( 1: 200000)Topical haemostatic :bleeding from mouth,

peptic ulcer, noseBronchial asthma – s.c. or inhalation (nebulized)

Page 22: SYMPATHETIC SYSTEM Sympathomimetic Agents

2.NORADRENALINE (Norepinephrine)

Released from post-ganglionic sympathetic nerves

10-20% of content of adrenal medullary secretion Receptor action:

α 1 , α 2 & β1

>

No effect on β2

Page 23: SYMPATHETIC SYSTEM Sympathomimetic Agents

Receptor action1

α2

1

2

Heart HR CO Arrhythmias Coronary flowBlood Pressure Systolic Mean Diastolic Muscle flow Cutaneous flow

Epinephrine+++

++++

++++

++++++

++++

+,0,-+++–

Norepinephrine ++ (slightly less) ++ + 0

– 0, – ++++ ++

+++ ++ ++ 0,+ –

Comparison of effects of Epinephrine and NE

Page 24: SYMPATHETIC SYSTEM Sympathomimetic Agents

Other effects:

Similar to Epinephrine Metabolic effects seen with larger doses Toxicity: Similar to Epinephrine but greater in BP Greater vasoconstriction : sloughing and necrosis

can occur at site of administration

Uses : Hardly used now except sometimes in peripheral vascular failure (eg. Septic shock).

Page 25: SYMPATHETIC SYSTEM Sympathomimetic Agents

DOPAMINEImmediate precursor of NENeurotransmitter in CNS (? Periphery)CVS effects:

Low conc. : D1 - Renal, mesenteric and coronary vasodilatation

glomerular filteration renal blood flow, Na excretion

Moderate Conc. : 1 - Positive inotropic effect on heart

in systolic BP and pulse pressure, ± on diastolic pressure

High Conc. : 1 - Generalized vasoconstriction

Page 26: SYMPATHETIC SYSTEM Sympathomimetic Agents

Other effects : Not significant.

Therapeutic Uses:- Severe CHF (sp. with oliguria) Cardiogenic and septic shock

Major Actions of DA are within the CNS

Five receptor subtypes (D1 to D5)

D1 – excitatory

D2 – inhibitory

Involved in behavioural functions, endocrine regulation

Page 27: SYMPATHETIC SYSTEM Sympathomimetic Agents

DRUG α1 α2 β1 β2 DA

Adrenaline +++ ++ +++ +++ 0

Noradrenaline +++ +++ ++ 0 0

Dopamine + 0 ++ 0 +++

Dobutamine +/- 0 +++ + 0

Isoprenaline 0 0 +++ +++ 0

Sympathomimetic Catecholamines

Page 28: SYMPATHETIC SYSTEM Sympathomimetic Agents